CytoSorbents Corporation (CTSO) Quote

https://finance.yahoo.com/news/cytosorbents-nasdaq-ctso-investors-sitting-101132136.html

"who have seen the share price tank a massive 90% over a three year period. That might cause some serious doubts"

What does a narcissistic sociopath do on a daily basis?

Besides heading to the bank every Friday with their ridiculous compensation checks, does anyone have a clue what this overpaid loser management is doing there everyday? Anyone? Buehler?

We'll have to see what unfolds ranch ! Something definitely smells bad imo.

What did they tell investors to get them to buy shares right before they collapsed? Chan vulnerable?

SHAREHOLDER ALERT:

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
NEWS PROVIDED BY

ACCESSWIRE

Jan 28, 2024, 12:00 PM ET

NEW YORK, NY / ACCESSWIRE / January 28, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ:CTSO). Such investors are advised to contact Danielle Peyton at newaction[ @, ext. 7980.

The investigation concerns whether Cytosorbents and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

https://www.kron4.com/business/press-releases/accesswire/828556/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cytosorbents-corporation-ctso/

Join the class action lawsuit and vote against Chan at upcoming annual meeting.

Silence from these incompetent overpaid buffoons. Not expecting any news today as they're all down at the bank cashing bloated checks paid for by the recent financing. What a disgusting group of clowns.

Companies used to pay Zack’s for coverage in their SCR service. Does not take away from any good news updates …

New article post from Zacks scr over on Yahoo about START-T numbers just out, has target of $4. Thanks Zee!

https... Zacks_SCR_Research_01172024_CTSO_Kerr.pdf

Pay attention to the claims in the coming class action lawsuit. You can certainly signup with the law firm for an earlier look. Interesting to learn what the investors were told to entice them into direct investment at $1.77 compared to where stock went afterwards. Trial results so far a bit of a disappointment. Maybe finally a time for management change ? We like Director Kim background and experience. Check her out. With long time Chairman having retired last year maybe no one on Board would oppose a change. Just one shareholder opinion…

What are the so called "claims" that are being made? Does anybody have specifics on this?

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
January 14, 2024 at 11:46 am EST
NEW YORK, Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at newaction @Oboeman-9980, ext. 7980.

CTSO new 52 week low

Here comes the Class Action against Cytosorbents !!!

https://www.accesswire.com/viewarticle.aspx?id=822116&lang=en

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

NEWS PROVIDED BY

ACCESSWIRE

Jan 04, 2024, 3:00 PM ET

"NEW YORK, NY / ACCESSWIRE / January 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ:CTSO). Such investors are advised to contact Danielle Peyton at newaction[ @, ext. 7980.

The investigation concerns whether Cytosorbents and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On December 28, 2023, Cytosorbents issued a press release announcing that its pivotal trial investigating the ability of its device candidate, DrugSorb®-ATR, to reduce perioperative bleeding in patients on ticagrelor (Brilinta®, Brilique® - AstraZeneca) undergoing cardiothoracic surgery before completing the recommended washout period, "did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries."

On this news, Cytosorbents' stock price fell $0.545 per share, or 33.44%, to close at $1.085 per share on December 28, 2023."

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP



View the original press release on accesswire.com

Can't delete the duplicates anymore they removed me from being a moderator.

Why do you think he hired a CFO that he had to let go after 3 months? Why did the longtime Chairman retire this year? Why isn’t he disclosing more about their grants and progress for the HemoDefend program?Are they still paying rent on the old facility?What did Bailee Gifford tell the investors to induce them to invest just a few weeks before their trial failure was announced? Transparency is not his ethic?

First thing that needs done after Chan is moved to CMO and an experienced successful CEO is chosen is to move over to the OTC market ASAP. They will burn up funds as fees are huge being on a major exchange. Every single dollar needs scrutinized going forward. I'd also like a huge more transparency shared to shareholders. What exactly is happening with new manufacturing facility now for instance?

That's all due to our great leadership which by the way needs to be replaced!

That's all due to our great leadership which by the way needs to be replaced!

Now they need only 30 mil more for a trial. Lol. Imagine got 90 mil when stock was at 9.00 and thats gone and Another another offering to dilute company 20% at 1.00. This thing is cooked 4ever. I will say either the product is all lies which it now appears to be or was just a scam all along. What a shame. I really thought this was a diamond in the rough but can it be if 15 years nothing done. And 1st 10 years nothing even tried. Just BS talk and lies. Joke and sad and delisted soon I’m sure. Dangerr

I would say they both have to go!

Chan and Capponi combine for what $3 milion a year. One has to ho and the other big cut. Period.

Do NOT vote for CHAN at the annual meeting. The old Chaiman that protected him for past decade is gone. Voice your displeasure by VOTING AGAINST CHAN

Hemoadsorption Therapy for Critically Ill Patients with Acute Liver Dysfunction: A Meta-Analysis and Systematic Review
by Caner Turan

1,2ORCID,Csenge Erzsébet Szigetváry 1,2ORCID,Tamás Kói 2,3,Marie Anne Engh 2ORCID,Isil Atakan 2,László Zubek 2,Tamás Terebessy 2,4,Péter Hegyi 2,5,6 andZsolt Molnár 1,2,7,*ORCID

1. Department of Anesthesiology and Intensive Therapy, Semmelweis University, 1085 Budapest, Hungary

2.Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary

3.Department of Stochastics, Institute of Mathematics, Budapest University of Technology and Economics, 1111 Budapest, Hungary

4.Department of Orthopaedics, Semmelweis University, 1085 Budapest, Hungary

5.Institute of Pancreatic Diseases, Semmelweis University, 1085 Budapest, Hungary

6.Institute for Translational Medicine, Medical School, University of Pécs, 7623 Pécs, Hungary

7.Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, 60-806 Poznan, Poland
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(1), 67; https://doi.org/10.3390/biomedicines12010067
Submission received: 16 November 2023 / Revised: 15 December 2023 / Accepted: 24 December 2023 / Published: 27 December 2023

URL:
https://www.mdpi.com/2227-9059/12/1/67

Still paying rent on the old factory!?

They sold 20% of the company for $1.33. This is NOT good. I would have preferred selling licenses or royalties, but I guess there is no serious buyer out there.

The only bright side is the execs and BoD bought a big chunk of shares.

Whew..just in time much needed cash raised by selling 7 million shares AND warrants through Jeffries this afternoon that will take them through third quarter 2024.. sounds like all rides on these trials.company dead if trials are weak or failure.

Doesn't everything really hinge on the trial results? Realistically, it's all moot if we don't get what we need there. I don't necessarily advocate firing Chan at this critical time, but I've been a long time critic of paying both him and Capponi president/CEO salaries all this time. That's a travesty. Ridiculous.

Clearly time for a management change/upgrade. The retirement of the Old Chaiman who protected Phil Chan opens the path for new talent. The newest Board member was brought on Board for her experience and expertise. Be sure to vote you proxy agains Phil Chan and for Kim. Ideally she becomes the ne CEO.
Ms. Kim is currently a Vice President at Zimmer Biomet, where she serves as the general manager of the Smart Implants portfolio and is responsible for leading the end-to-end program and product management for Zimmer Biomet’s Smart Implants technology in the orthopedic field. Previously, Ms. Kim served as Vice President, Global Strategic Marketing and Chief of Staff for the General Manager, Depression at LivaNova from 2020 to 2021. Prior to LivaNova, from 2011 to 2020, Ms. Kim served in increasing roles of responsibility at Johnson & Johnson Medical Devices. Ms. Kim received her MBA at the MIT Sloan School of Management, and she received a dual degree from the University of Pennsylvania with a B.S. in Economics from The Wharton School and a B.A. in Political Science from The College of Arts and Sciences.

Why is there no talks of the huge factory they built to be ready for the future demand. The rent must be crazy. Does Chan speak of it in quarterly

It could be toxic dilution imo.

Who is selling shares at 4 1/2 cents presplit. The trial news should be amazing for the share price!

It works allright. Shorts won't be able to keep it down when it receives FDA Breakthrough approval and price soars.

It works alrite. Workin the stock price to .33 which would make shareholders back to the RS price 15 years ago. My good I could run this company better with just sending reps that can talk the info to hospitals in the EU. Joke. And Sad

they have sold over 200,000 cartridges already, it works.

"poison pill" in place to prevent that...

How this ever happen is making me think that this product and pipelines don’t even work. 15 years??? Would have been scooped up already. I fear bankrupsy soon imo

Not happy with how it ever was able to happen but glad the D'Amico saga is done and that we paid no severance. Somebody should have to pay for this but I won't hold my breath.

I'm assuming your talking about today's filter/shock use news regarding Brazilian codes. If this begins to catch on it would get our filters in ambulances 🚑️ which could drive revenues thru the roof !
I think that is just one of the strategies.

News and nothing. Looks like death

You gonna sell shares if it does break lower? We may see the typical end of year tax loss selling. I'm holding with the ship at this point. FDA submission just around the corner.

If support breaks here back to 1.00

CLINICAL TRIAL article
Front. Pediatr.
Sec. Pediatric Critical Care
Volume 11 - 2023 | doi: 10.3389/fped.2023.1259384
Impact of CytoSorb and CKRT on hemodynamics in pediatric patients with septic shock: the PedCyto study
study
Gabriella Bottari1, 2* Isabella Guzzo1, 3 Andrea Cappoli1, 3 Raffaella Labbadia1, 3 Salvatore Perdichizzi1, 2 Carmela Serpe1 Jacques Creteur4, 5 Corrado Cecchetti1, 2 Fabio Silvio Taccone4, 5
1Bambino Gesù Children's Hospital (IRCCS), Italy
2Pediatric Intensive Care Unit Children's Hospital Bambino Gesù, Italy
3Unit of Nephrology and Dialysis, Department of Specialized Pediatrics and Kidney Liver Transplantation, Bambino Gesù Children's Hospital (IRCCS), Italy
4Hôpital Erasme, Université libre de Bruxelles, Belgium
5Service de Soins Intensifs, Hôpital Erasme, Université Libre de Bruxelles, Belgium

Background: There is a lack of data to support the use of hemoadsorption in pediatric septic shock.The aim of our study was to assess the effectiveness and safety of Cytosorb therapy in this setting.Phase II interventional single arm pilot study in which 17 consecutive children admitted with septic shock who required continuous kidney replacement therapy (CKRT) and weighed ≥ 10 kg were included. A CytoSorb (CytoSorbents Inc, New Jersey, USA) hemoadsorption cartridge was added to the CKRT every 24 hours for a maximum of 96 hours. A control group of 13 children with septic shock treated with CKRT but not hemoadsorption at Children's Hospital Bambino Gesù and enrolled in the EuroAKId register was selected as an historical cohort. The primary outcome of the study was a reduction in vasopressor or inotrope dose of > 50% from baseline by the end of Cytosorb therapy. Secondary outcomes included hemodynamic and biological changes, changes in severity scores, and 28-day mortality.Results: There were significant decreases in the Vasoactive Inotropic Score (VIS) and the Pediatric Logistic Organ Dysfunction 2 (PELOD-2) score at 72 and 96 hours from the start of the Cytosorb therapy compared to baseline; the reductions were larger in the hemoadsorption group than in the control group (historical cohort). 28-day mortality was lower, although not significantly, in the hemoadsorption group when compared to the control group (5/17 [29%] vs. 8/13 [61%] OR 0.26 [95% CI 0.05-1.2]; p= 0.08).
Conclusions: CytoSorb therapy may have some benefits in pediatric patients with septic shock. Future larger randomized trials are needed in this setting.

Received: 15 Jul 2023; Accepted: 21 Aug 2023.
Copyright: © 2023 Bottari, Guzzo, Cappoli, Labbadia, Perdichizzi, Serpe, Creteur, Cecchetti and Taccone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Gabriella Bottari, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

https://www.frontiersin.org/articles/10.3389/fped.2023.1259384/abstract

At next Board meeting does Dr. Chan get replaced by Jiny Kim?

NEWS -- CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial



Readout of topline results expected before year-end on FDA Breakthrough Device, DrugSorb-ATR. Sets stage for potential regulatory submission to FDA and Health Canada as the first reversal agent for the blood thinner, Brilinta®

PRINCETON, N.J., Aug. 14, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has completed the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) randomized, controlled trial, following the last scheduled patient follow-up. The STAR-T trial is evaluating the ability of DrugSorb®-ATR to reduce perioperative bleeding due to the widely-used blood thinner, ticagrelor (Brilinta®, AstraZeneca) in patients undergoing cardiothoracic surgery.

Dr. Efthymios N. Deliargyris, Chief Medical Officer of CytoSorbents stated, "We are very pleased to complete all patient related procedures in the STAR-T trial without a single study subject lost to follow-up. This is another critical step of the process delivered on time and with 100% success. We are focused on ensuring complete and high-quality study data collection, ultimately leading to database lock and triggering the statistical analyses that will provide the readouts of the trial. We continue to expect topline results by the end of the year."

Brilinta® is one of the leading "blood thinners" used as part of dual-antiplatelet therapy in patients suspected of having a heart attack. However, in the up to 10% of patients that are not eligible for a cardiac stent and now require coronary artery bypass graft (CABG) surgery, Brilinta confers a risk of major fatal or life-threatening CABG-related bleeding as high as 50-65%, particularly if the surgery is performed within the first five days of receiving the drug. Waiting in the hospital to wash out the drug is the only acceptable alternative, but comes at high cost and potential clinical risk. The goal of using DrugSorb-ATR is to allow patients to get the critical surgery they need without delay, while reducing or preventing this bleeding risk by actively removing the drug from blood during the surgery when installed in the heart-lung machine. DrugSorb-ATR has received FDA Breakthrough Device Designation for this indication. The STAR-T pivotal study was conducted by many leading cardiothoracic surgery centers in North America and is intended to support U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in this application.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its flagship product, CytoSorb®, is approved in the European Union, distributed in 75 countries worldwide, and has accumulated more than 212,000 human treatments to date, to reduce "cytokine storm" and other toxins that can cause organ failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, has received two U.S. FDA Breakthrough Device Designations to remove two separate blood thinners during cardiothoracic surgery, including ticagrelor and the direct oral anticoagulants (DOAC) apixaban and rivaroxaban, and is undergoing pivotal clinical studies. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, statements about potential exposures resulting from our cash positions, representations and contentions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2023, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

CytoSorbents Contact:
Kathleen Bloch
(732) 398-5429
mailto://kbloch@cytosorbents.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/cytosorbents-completes-us-and-canadian-star-t-pivotal-trial-301899656.html

SOURCE CytoSorbents Corporation

They will have no choice but to fire him. As a result, a POS like this bum will sue the company which result in us paying him to go away OR enduring an expensive court case. I'm guessing the former since we were dumb enough to hire him. What's our defense in court? We were stupid and didn't check him out?

I've got a bunch of 2.50 calls set to expire on friday. Notice how this type of crap almost always coincides with option expiration date. Gdmt Chan !

I have no idea. I periodically do a Google search last 24 hours on "Cytosorbents" and it popped up as a story few nights back. Fantom, I'm not at all pleased with Chan as the driver. At this point there's not much we can do. I would hope the majority CTSO stock holders demand a BOD to straighten things like this out should it get approved next year !

Did they only find this out because of your post? I emailed it to them twice demanding he be fired.